Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tourian

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
International Clinical Psychopharmacology|August 16, 2008
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trialPatrice Boyer, Stuart Montgomery, Ulla Lepola, et al.
Current Medical Research and Opinion|March 12, 2015
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysisMichael E Thase, Rana Fayyad, Ru-Fong J Cheng, et al.
International Clinical Psychopharmacology|June 12, 2008
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderDaniel Z Lieberman, Stuart A Montgomery, Karen A Tourian, et al.
International Clinical Psychopharmacology|August 1, 2015
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysisAnita H Clayton, Eunhee Hwang, Susan G Kornstein, et al.
Journal of Clinical Psychopharmacology|January 16, 2010
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trialKarl Rickels, Stuart A Montgomery, Karen A Tourian, et al.
Drug and Alcohol Dependence|May 17, 2000
Baseline prediction of 7-month cocaine abstinence for cocaine dependence patientsA I Alterman, J R McKay, F D Mulvaney, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
International Clinical Psychopharmacology|August 16, 2008
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trialPatrice Boyer, Stuart Montgomery, Ulla Lepola, et al.
Current Medical Research and Opinion|March 12, 2015
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysisMichael E Thase, Rana Fayyad, Ru-Fong J Cheng, et al.
International Clinical Psychopharmacology|June 12, 2008
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderDaniel Z Lieberman, Stuart A Montgomery, Karen A Tourian, et al.
International Clinical Psychopharmacology|August 1, 2015
Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysisAnita H Clayton, Eunhee Hwang, Susan G Kornstein, et al.
Journal of Clinical Psychopharmacology|January 16, 2010
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trialKarl Rickels, Stuart A Montgomery, Karen A Tourian, et al.
Drug and Alcohol Dependence|May 17, 2000
Baseline prediction of 7-month cocaine abstinence for cocaine dependence patientsA I Alterman, J R McKay, F D Mulvaney, et al.
Pageof 4